Business Wire

CA-TETRATE

12.4.2022 14:09:16 CEST | Business Wire | Press release

Share
Tetrate Adds Istio and Envoy Support for Arm Neoverse

Tetrate, founded by creators and maintainers of Istio and Envoy, today announced that Istio service mesh and Envoy proxy now support the Arm® Neoverse™ platform. Arm is the leading technology provider of processor IP and its designs have enabled more than 215 billion chips. Neoverse support enables widely used open source software projects to run faster, with less energy usage and lower total cost of ownership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005425/en/

Neoverse is available on a wide range of cloud environments and for large-scale data center environments. Neoverse implementations include AWS Graviton2 processor-based Elastic Compute Cloud (Amazon EC2) instances, which offer a price/performance improvement of up to 40% over comparable x86-based instances.

“The diversity of applications is rapidly changing, and Arm is addressing the growing need for increased performance to take on compute-intensive workloads like service mesh,” said Bhumik Patel, director of ecosystem development, Infrastructure Line of Business, Arm. “By partnering with Tetrate to add Istio and Envoy support to Neoverse based platforms, we can bring better application performance, reduced energy consumption and lower TCO to customers of this industry-leading service mesh software.”

Neoverse is particularly well suited for complex workloads such as machine learning, AI, and now, service mesh . For example, AWS previewed Amazon EC2 instances powered by next-generation AWS Graviton3 processors, which will provide up to 25% better performance for compute-intensive workloads compared to current generation instances powered by Graviton2. AWS Graviton3 processors will deliver up to 2x higher floating-point performance for scientific and machine learning workloads, and will provide 50% higher memory bandwidth versus Graviton2-based instances to improve the performance of memory-intensive applications like scientific computing.

“We at Tetrate are seeing larger and more complex service mesh deployments that demand innovative solutions for meeting SLAs cost-effectively from edge to the cloud,” said Saptak Sen, vice president of Strategic Alliances at Tetrate. “We are proud to work with Arm, AWS, and the rest of the Envoy and Istio communities to help our customers in government, finance, ecommerce, and other markets make their mesh implementations more consistent, flexible, and scalable.”

Why Faster Performance is Important for Service Mesh

A service mesh is made up of microservices software instances which are created and destroyed to meet the capacity needs of an application at runtime. Each service instance is accompanied by a proxy instance, and messages between services are routed through the proxy instances.

Each message between services, or between services and the control plane, is authenticated, authorized, and encrypted/decrypted, boosting security. All of this work is compute-intensive, and encryption and decryption in particular are numerically intensive. Faster performance from the underlying hardware infrastructure can make a tremendous difference in the responsiveness of the service mesh.

Istio is the leading service mesh, and Istio software includes an extended version of the Envoy proxy. Tetrate is optimizing Istio and the Envoy proxy for performance. Neoverse supports these efforts and gives a solid boost to Istio and Envoy performance. Accelerating these software projects also yields higher performance when running Tetrate’s industry-leading service mesh management software, Tetrate Service Bridge.

How Istio Service Mesh Delivers for Government and Industry

Istio service mesh, accelerated by Arm Neoverse on multiple platforms, supports a number of benefits important to government and industry:

  • Security . Service mesh performs authentication, authorization, and encryption/decryption on every communication among service instances and with the control plane, enhancing security. Neoverse speeds the necessary processing, including numerical processing for encryption and decryption.
  • Agility . Service mesh supports rapid software development using continuous integration/continuous delivery (CI/CD) approaches. Neoverse provides a platform for accelerated performance, which can be managed and enhanced across software updates.
  • Business continuity . With service mesh, architects can create applications that can fail over from on-premises to cloud, from one availability zone in the cloud to another, and even from one cloud to another. Neoverse support is available on all these platforms, giving applications consistent performance optimization across all deployment targets.

Download Arm-Ready Versions of Istio

Those interested can download Arm-ready versions of Istio from Tetrate Labs. Options include a FIPS version, compliant with Federal Information Processing Standard (FIPS) 140-2, Security Requirements for Cryptographic Modules. And the number of options for accessing Istio running on Neoverse across multiple platforms is large and growing. To learn more, contact Tetrate .

About Arm

Arm technology is at the heart of a computing and data revolution that is transforming the way people live and businesses operate. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 215 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners we are at the forefront of designing, securing and managing all areas of AI-enhanced connected compute from the chip to the cloud.

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye